Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases. The company developed Tyzeka/Sebivo through a co development agreement with Novartis Pharma AG for the treatment of patients with chronic hepatitis B in the United States and European Union for the treatment of patients with chronic hepatitis B. It also focuses on the treatment of infections caused by hepatitis C virus (HCV) and human immunodeficiency virus (HIV). The company’s preclinical HCV nucleoside polymerase inhibitor program comprises two novel nucleotide prodrugs, IDX184 and IDX102. Idenix also completed a phase I dose-escalation study for the non-nucleoside reverse transcriptase inhibitor candidate, IDX899 for the treatment of HIV. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis AG.